INTEGRA LIFESCIENCES HOLDINGS CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IART in the last 30 days.
See all $IART insider activity →Integra LifeSciences reported Q3 2026 revenue of $411.2M, up 2.3%, with GAAP EPS of $0.19 and adjusted EPS of $0.59. The company refinanced $2.1B in debt, increasing interest costs. BTIG maintains a Neutral rating, citing operational challenges and elevated leverage.
Truist reduced its price target for Integra LifeSciences from $15 to $13, keeping a Hold rating. The stock is currently trading at $12.04, down 2.27% on the day and 9.84% over the past year.
Citigroup maintained a Neutral rating on Integra Lifesciences (IART) but lowered its price target from $15.00 to $14.00. GuruFocus values IART at $20.43, suggesting a 40.6% undervaluation. The company has a GF Score of 69/100, indicating fair performance. IART operates in the medical devices sector and faces challenges in growth and financial strength.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning IART (INTEGRA LIFESCIENCES HOLDINGS CORP). Coverage has skewed bearish: 1 bullish, 0 neutral, and 8 bearish.
Recent IART coverage spans earnings, financial news and corporate actions.
Higher debt cost likely pressures earnings and may weigh on the stock.
Analyst downgrade suggests weaker outlook.
Analyst price‑target cut suggests weaker near‑term expectations.
Citizens reaffirmed its Market Outperform rating on Integra Lifesciences, setting a $22 price target, suggesting an 85.8% upside from the Oct 21 close. The analyst highlights the company's progress in tissue technologies and resilient performance despite challenges, citing growth in neurosurgery and leadership as positive factors.
Analyst downgrade suggests lower near‑term upside.
AlphAI scores every news story that mentions IART with an AI model for sentiment and relevance, and aggregates insider trades from INTEGRA LIFESCIENCES HOLDINGS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Integra LifeSciences reported Q3 2026 revenue of $411.2M, up 2.3%, with GAAP EPS of $0.19 and adjusted EPS of $0.59. The company refinanced $2.1B in debt, increasing interest costs. BTIG maintains a Neutral rating, citing operational challenges and elevated leverage.
3 min readTruist reduced its price target for Integra LifeSciences from $15 to $13, keeping a Hold rating. The stock is currently trading at $12.04, down 2.27% on the day and 9.84% over the past year.
1 min readCitigroup maintained a Neutral rating on Integra Lifesciences (IART) but lowered its price target from $15.00 to $14.00. GuruFocus values IART at $20.43, suggesting a 40.6% undervaluation. The company has a GF Score of 69/100, indicating fair performance. IART operates in the medical devices sector and faces challenges in growth and financial strength.
2 min readCitizens reaffirmed its Market Outperform rating on Integra Lifesciences, setting a $22 price target, suggesting an 85.8% upside from the Oct 21 close. The analyst highlights the company's progress in tissue technologies and resilient performance despite challenges, citing growth in neurosurgery and leadership as positive factors.
1 min readWells Fargo reduced its price target for Integra LifeSciences (IART) from $15 to $13, maintaining an Equal Weight rating. The firm cited Q3 results meeting guidance but emphasized concerns about recovery pace and offsetting factors like Neuro strength and product relaunch.
1 min readCitizens cut Integra LifeSciences' (IART) price target to $22 from $25, citing Q3 2026 revenue miss and facility flooding. IART stock is down 12.5% weekly. Q3 revenue was $411.2M, slightly below estimates, but EPS beat at $0.59. Flooding impacted Q3 revenue by $7M and may affect Q4 by $15M-$20M.
1 min readIntegra (IART) reported Q3 EPS of $0.59, beating estimates by $0.03, but revenue of $411.2M missed expectations. Guidance for Q4 and FY 2026 was below consensus. The stock is down 40.17% over the last 3 months.
3 min readINTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Integra LifeSciences Reports Third Quarter 2026 Financial Results PRINCETON, N.J., October 21, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending
3 min readIntegra LifeSciences Holdings completed a $450 million senior secured notes offering on 10/19/2026. The company's stock has seen a 5-day change of +1.82% and a year-to-date change of +8.29%. Previously, Truist Securities adjusted its price target to $15 from $19.
1 min readINTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Integra Announces Completion of Refinancing Transactions PRINCETON, N.J., Oct 19, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.5
1 min read
